Departments & Organizations
Skin Diseases Research Center, Yale
Stem Cell Center, Yale: Stem Cell Niche and Homing | Stem Cell Self-Renewal and Cell Symmetry
Yale Center of Excellence in Hematology (YCEH)
Yale Combined Program in the Biological and Biomedical Sciences (BBS): Immunology: Computational Immunology; Consequences of an Immune Response; Infectious Disease and Host-Pathogen Interaction; Lymphocyte Development; Mounting an Immune Response
Dr. Flavell is Sterling Professor of Immunobiology at Yale University School of Medicine, and an Investigator of the Howard Hughes Medical Institute. He received his B.Sc. (Honors) in 1967 and Ph.D. in 1970 in biochemistry from the University of Hull, England, and performed postdoctoral work in Amsterdam (1970-72) with Piet Borst and in Zurich (1972-73) with Charles Weissmann. Before accepting his current position in 1988, Dr. Flavell was first Assistant Professor (equivalent) at the University of Amsterdam (1974-79); then Head of the Laboratory of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, London (1979-82); and subsequently President and Chief Scientific Officer of Biogen Research Corporation, Cambridge, Massachusetts (1982-88). Dr. Flavell is a fellow of the Royal Society, a member of the National Academy of Sciences as well as the Institute of Medicine. Richard Flavell uses transgenic and gene-targeted mice to study Innate and Adaptive immunity, T cell tolerance and activation in immunity and autoimmunity,apoptosis, and regulation of T cell differentiation.
Education & Training
|PhD||Hull University (1970)|
|EMBO Postdoctoral Fellow with Prof. C. Weissmann||Universitat Zurich|
|Postdoctoral Fellow with Professor Piet Borst||University of Amsterdam|
Honors & Recognition
The Vilcek Prize in Biomedical ScienceVilcek Foundatioin (2013)
The William B. Coley Award for Distinguished Research in Basic and Tumor ImmunologyCancer Research Institute (2012)
Mouse Model to Evaluate Attenuated Vaccine Candidates Switzerland (2008)
The primary objective of this proposal is to generate a humanized mouse model in which critical components of the human immune system replace the homologous regions of the mouse.